Cyclops Syndrome After Anterior Cruciate Ligament Reconstruction (SCALA)
Effect of Botulinum Toxin on Hamstring Contracture and the Occurrence of Cyclops Syndrome After Anterior Cruciate Ligament Reconstruction
Monocentric, prospective, randomised, double-blind study of two parallel groups of 66 patients with post-reconstruction ACL hamstring contracture treated with an ultrasound-guided injection at two points on the body of the hamstring
- Group 1: botulinum toxin: 100 units (0.5ml) in 1 injection
- Group 2: placebo: 0.5 ml in 1 injection
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Alexandre Hardy, MD
- Phone Number: 33 189164500
- Email: alexandre.hardy@me.com
Study Locations
-
-
-
Paris, France, 75005
- Clinique du Sport
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patient over 18 years of age
- Patient who has read and signed the consent form for participation in the study
- Patient operated on for primary ACL ligamentoplasty with or without meniscal repair
- Patient with reducible flatus >10° at 1 month post ligamentoplasty
Exclusion Criteria:
- Revision ligamentoplasty
- Multi-ligament knee
- Patient under court protection, guardianship or trusteeship
- Patient not affiliated to the French social security system
- Patient participating in another therapeutic protocol
- Pregnant woman or woman of childbearing age without effective contraception
- Patient unable to understand the informed information and/or to give written informed consent: dementia, psychosis, disturbed consciousness, non-French speaking patient
- Patient with known hypersensitivity to botulinum toxin
- Patient with peripheral neuromuscular dysfunction or pronounced atrophy of the semitendinosus muscle
- Patient treated with anticoagulants, chloroquine (or hydroxychloroquine)
- Patient treated in the previous seven days with antibiotics or muscle relaxants (such as tubocurarine)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Group 1
botulinum toxin: 100 units (0.5ml) in 1 injection
|
100 units (0.5ml) in 1 injection
|
|
Placebo Comparator: Group 2
Placebo: 0.5 ml in 1 injection
|
Placebo 0.5 ml in 1 injection
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The percentage of therapeutic success, defined by the absence of extension defect at M3 post ligamentoplasty, will be compared between the groups by a Chi-2 test.
Time Frame: Month 2
|
Therapeutic success is defined by the absence of extension defect (0 degree of flessum) at 2 months post botulinum toxin injection
|
Month 2
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Alexandre Hardy, MD, Clinique du Sport
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Joint Diseases
- Musculoskeletal Diseases
- Muscular Diseases
- Contracture
- Amino Acids, Peptides, and Proteins
- Proteins
- Biological Factors
- Hydrolases
- Enzymes
- Enzymes and Coenzymes
- Metalloendopeptidases
- Endopeptidases
- Peptide Hydrolases
- Metalloproteases
- Bacterial Proteins
- Bacterial Toxins
- Toxins, Biological
- Botulinum Toxins
Other Study ID Numbers
Other Study ID Numbers
- 2020-005742-42
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.